Most Recent
Korean drug company Samsung Bioepis has filed a second lawsuit seeking to invalidate German drug company Fresenius Kadi's patent for a biosimilar of blockbuster arthritis drug Humira.
The law firm that lost the first ever application for a group costs order in class actions against ANZ and Westpac has indicated it will revive its bid, tweaking a retainer agreement with group members in hopes of winning the court's approval this time.
Samsung Australia has been slapped with a $14 million penalty for running ads that misrepresented that its Galaxy smartphones could be used in pool and sea water.
The Scotch Whisky Association has sued an Australian food and drink importer for “flagrant” copyright infringement after it allegedly sold regular whisky with the trade organisation’s 'scotch whisky' certification trade mark.
A class action alleging the federal government contaminated Indigenous land with toxic firefighting foam has lost a challenge to a report by a scientist who declined to find that the foam could cause adverse health effects including immunosuppression and interfere with the efficacy of vaccines.
Mills Oakley has poached a leading employment law partner from King & Wood Mallesons for its growing workplace relations team.
Top tier law firm King & Wood Mallesons has lured leading competition lawyer Luke Woodward to bolster its regulatory practice.
QSuper has hit back at a class action over its alleged failure to notify members of changes to its premiums, saying group members failed to heed a “large font” notice of the changes and that any recoveries cannot be paid out to the law firm and funder running the litigation.
The litigation funder backing two combustible cladding class actions has sold a third of its investment in the cases to a player in the nascent secondary market for class action financing.
Forex Capital Trading liquidators have won an “urgent” bid for orders allowing them to distribute $69.5 million to 8,600 former customers of the derivatives trader which allegedly gave misleading advice on products described as “little more than gambling”.